ผู้เขียน: Mousmee Sharma

Dr Parteek Prasher, Assistant Professor, Department of Chemistry, University of Petroleum and Energy Studies, holds a research experience of 8 years in medicinal chemistry and biomaterials while working in the field of anti-inflammatory and anticancer chemotherapy. The research team led by Dr Prasher focuses on the development of rationally designed molecules for targeting various disorders, including inflammation, cancer, and antimicrobial MDR, which also includes the identification of novel pharmacophores, chemical moieties, and APIs for developing potential chemotherapeutics. With several national/international collaborations, Dr. Prasher has published more than 100 peer-reviewed publications in journals of repute. Dr. Prasher has been a recipient of the prestigious Junior/ Senior Research Fellowship by the Council of Scientific and Industrial Research, Government of India (2012–2015). He received the ‘Lectureship’ Award from the Government of India (2012). He isalso a recipient of the Teachers Associateship for Research Fellowship (TARE) and a research grant by the Science and Engineering Research Board of the Department of Science and Technology, Government of India for 3 years, from December 2021 to December 2024. Dr Mousmee Sharma,  Assistant Professor, Department of Chemistry, Uttaranchal University, has research experience of more than 5 years in physical chemistry and biomaterials while working in the field of biomembranes. The recent research work of Dr. Mousmee is focused on the development of mucoadhesive materials for drug delivery across the physiological mucus barrier. Dr. Mousmee has published 50 research/review articles and 20 book chapters in journals of high repute. A ‘Gold Medalist’ in her post-graduation. Dr. Sachin Kumar Singh, a Professor at School of Pharmaceutical Sciences, Lovely Professional University, India, holds his Master of Pharmacy in Pharmaceutical Analysis from J.S.S. College of Pharmacy, Ooty, Tamil Nadu, India, and holds Ph D degree in Pharmaceutical Sciences from Karpagam University, Coimbatore, India. He has completed one DST-SERB-funded project on the development of SNEDDS of polypeptide-k for the treatment of diabetes mellitus. Dr. Singh has published more than 200 research papers with a cumulative impact of 400 and co-authored 10 book chapters. He has two Indian patents and two Australian patents. He has reviewed more than 75 research papers upon invitation from publishers of high repute. He has graduated 8 Ph D students and 30 M pharmacy students and currently graduating 3 masters and 6 Ph D students. Currently, his h index is 27 with total citations > 2300. In January 2020, he received Dr. B.C. Deb Memorial Award for the popularization of science by the Indian Science Congress Association at 107th Indian Science Congress held at UAS Bengaluru. He is the first recipient from the field of Pharmaceutical Sciences to receive this award. He is also a recipient of the 2014 Bharat Shiksha Ratan Award given by the Global Society for Health and Educational Growth, Delhi, India. His core area is improving the oral bioavailability of poorly water-soluble drugs using various formulation approaches, including nanotechnology, complexation, solid dispersion, liquisolid technology, etc. Dr. Ronan Mac Loughlin is currently Associate Director R&D, Science and Emerging Technologies, Aerogen Limited, an Irish medical device company specializing in respiratory drug delivery. He has more than 16 years of experience in the design and development of aerosol drug delivery systems and drug-device combinations. He currently has more than 70 articles, conference presentations, and conference papers, combined with several patent applications currently under review. He holds the position of Adjunct Associate Professor in Trinity College Dublin’s (Ireland) Department of Pharmaceutics and Pharmaceutical Technology, Honorary Senior Lecturer in the Royal College of Surgeons Ireland (RCSI), Chairman of the Enterprise Ireland Funded Medical Engineering Technology (MET) Gateway, and Chairman of the Industry Advisory Group for CURAM, the Science Foundation Ireland-funded medical device research center. Additionally, he is currently co-chair of the pediatric and CF working group within the International Society for Aerosols in Medicine (ISAM). Dr. Kavita Pabreja holds a doctoral degree in Drug Discovery Biology from Monash Institute of Pharmaceutical Sciences, Monash University, Australia. Dr. Pabreja’s lecturing experience covers more than 5 years across national and international universities.  Her research experience includes more than 10 years of laboratory-based research focused on understanding the downstream signaling pathways associated with GLP-1R in diabetes using new-generation sequencing (NGS) technology, RNA-Seq, and investigating the pathogenesis underlying diabetic neuropathic pain and inflammation.  She published more than 21 original research and review articles in high-quality peer-reviewed journals. Currently, Dr. Pabreja is utilizing her knowledge and skills in the role of Regulatory Affairs Coordinator with a leading Australian novel vaccine research company. Dr Kamal Dua, Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), has a research experience of over 12 years working in the field of drug delivery targeting inflammatory diseases. Dr Dua is also a leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step toward translation into clinics. Dr Dua’s key research areas are drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as interleukins and micro RNAs and developing new and effective drug delivery formulations for the management of inflammation in chronic airway diseases and cancer.